O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
-0.47%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$5.5M
AUM Growth
+$5.5M
(-100%)
Cap. Flow
-$176M
Cap. Flow
% of AUM
-3,203.7%
Top 10 Holdings %
Top 10 Hldgs %
32.29%
Holding
153
New
11
Increased
26
Reduced
36
Closed
14
Top Buys
| 1 |
SVA
Sinovac Biotech, Ltd
SVA
|
$349K |
| 2 |
Xenon Pharmaceuticals
XENE
|
$19.6K |
| 3 |
Mersana Therapeutics
MRSN
|
$19.5K |
| 4 |
Travere Therapeutics
TVTX
|
$18.7K |
| 5 |
Progyny
PGNY
|
$18.2K |
Top Sells
| 1 |
DexCom
DXCM
|
$76.7M |
| 2 |
NSTG
NanoString Technologies, Inc.
NSTG
|
$40.2M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
$16.5M |
| 4 |
Illumina
ILMN
|
$15.8M |
| 5 |
Galapagos
GLPG
|
$12.9M |
Sector Composition
| 1 | Healthcare | 98.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KDNY
51
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $33.2K | 0.6% |
1,896,300
+478,000
| +34% | +$8.36K |
|
52
Vaxcyte
PCVX
$4.12B
| $32.9K | 0.6% |
1,513,659
| – | – |
|
53
Aclaris Therapeutics
ACRS
$219M
| $32.5K | 0.59% |
2,325,500
+745,600
| +47% | +$10.4K |
|
54
Iovance Biotherapeutics
IOVA
$800M
| $30.9K | 0.56% |
2,798,441
-3,834,565
| -58% | -$42.3K |
|
|
VRNA
55
Verona Pharma
VRNA
$9.18B
| $23.9K | 0.43% |
5,694,841
| – | – |
|
56
scPharmaceuticals
SCPH
$296M
| $23.1K | 0.42% |
4,797,148
| – | – |
|
57
Biogen
BIIB
$20.9B
| $22.8K | 0.41% |
111,600
-6,300
| -5% | -$1.29K |
|
58
TELA Bio
TELA
$65M
| $21.2K | 0.38% |
3,027,542
| – | – |
|
59
Passage Bio
PASG
$22.5M
| $21.1K | 0.38% |
8,931,999
+1,600,000
| +22% | +$3.78K |
|
|
DBTX
60
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
| $20.8K | 0.38% |
4,945,192
| – | – |
|
61
Neuropace
NPCE
$305M
| $19.9K | 0.36% |
4,012,281
| – | – |
|
62
RxSight
RXST
$363M
| $19.5K | 0.35% |
1,383,500
| – | – |
|
63
MeiraGTx Holdings
MGTX
$590M
| $18.9K | 0.34% |
2,501,618
-795,048
| -24% | -$6.02K |
|
|
64
Travere Therapeutics
TVTX
$1.71B
| $18.7K | 0.34% |
+772,200
| New | +$18.7K |
|
|
65
Progyny
PGNY
$2B
| $18.2K | 0.33% |
+625,000
| New | +$18.2K |
|
66
Gilead Sciences
GILD
$140B
| $17.8K | 0.32% |
287,600
| – | – |
|
67
ALX Oncology
ALXO
$54.1M
| $17.7K | 0.32% |
2,186,269
+1,564,569
| +252% | +$12.7K |
|
68
Ionis Pharmaceuticals
IONS
$9.65B
| $16.8K | 0.3% |
+453,400
| New | +$16.8K |
|
69
Invivyd
IVVD
$211M
| $16.6K | 0.3% |
5,056,000
| – | – |
|
70
uniQure
QURE
$944M
| $16.3K | 0.3% |
874,849
-44,400
| -5% | -$828 |
|
71
GH Research
GHRS
$864M
| $16.2K | 0.29% |
1,622,060
+193,328
| +14% | +$1.93K |
|
72
RAPT Therapeutics
RAPT
$192M
| $15.8K | 0.29% |
866,396
+505,096
| +140% | +$9.22K |
|
73
Ventyx Biosciences
VTYX
$185M
| $15.8K | 0.29% |
1,289,280
| – | – |
|
74
Amgen
AMGN
$152B
| $13.9K | 0.25% |
57,100
| – | – |
|
|
BLU
75
DELISTED
BELLUS Health Inc.
BLU
| $13.4K | 0.24% |
1,454,800
| – | – |
|